All In Biotech

Drug Trial Radar · NCT06997159

A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).

A Randomized, Multicentre, Observer-blind Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Regimens and Miltefosine as an Active Control in Patients With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Jun 15, 2026

Primary completion

Apr 5, 2028

Study completion Apr 5, 2028

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis Pharmaceuticals
First posted
May 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to measure efficacy, safety and pharmacokinetics (PK) of two LXE408 oral regimens and oral miltefosine tablets as active control in localized cutaneous leishmaniasis in the region of the Americas (AMR), and assess its suitability for use in monotherapy for the treatment of patients with cutaneous leishmaniasis (CL).

Conditions

  • Localized Cutaneous Leishmaniasis

Interventions

  • LXE408Drug

    LXE408 film-coated tablets.

  • Miltefosine 50 MG Oral Capsule [Impavido]Drug

    Each capsule contains 50 mg miltefosine in an opaque, red, hard gelatin capsule. Capsules are supplied in packs of 56 capsules sealed in 8 aluminum blister stripes, each containing 7 capsules.

  • Placebo to LXE408Drug

    Film-coated tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieved Cure at Day 180Time frame: 180 days

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Foundation of Tropical Medicine Dr. Heitor Vieira Dourado

    Manaus, Amazonas, Brazil

  • Federal University of Maranhão

    São Luís, Maranhão, Brazil

  • Julio Muller University Hospital/ Federal University of Mato Grosso

    Cuiabá, Mato Grosso, Brazil

  • René Rachou Institute /Oswaldo Cruz Foundation- FIOCRUZ MINAS

    Belo Horizonte, Minas Gerais, Brazil

  • Instituto Conmemorativo Gorgas de Estudios de la Salud

    Panama City, Panama

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.